ROGERS, Conn. _ Rogers Corp. on Wednesday reported first-quarter net income of $27 million. For the current quarter ending in July, Rogers Corp. expects its per-share earnings to range from $1.16 to $1.26. Analysts surveyed by Zacks had forecast adjusted earnings per share of $1.13.
Kevin O’Leary says now is the buying opportunity of a lifetime in Europe.
--Abiomed Inc rescheduled second-quarter conference call to Nov. 1 at 8 am Eastern Time. --Accelrys Inc rescheduled third-quarter results to Oct. 31, after market. Its conference call will be held on Nov. 1, 9.30 am Eastern Time.
--Acorda Therapeutics Inc: rescheduled third-quarter financial results and conference call to Oct. 31 from Oct. 30. --Advent Software Inc reschedules third-quarter results and conference call to Oct. 30. --AGCO Corp rescheduled third-quarter results to Oct 31, 8 am Eastern Time from Oct. 30.
--Martha Stewart Living Omnimedia Inc rescheduled third-quarter results to Nov. 1 from Oct. 30. --Vertex Pharmaceuticals Inc rescheduled third-quarter 2012 earnings and conference call to after markets close on Nov. 1 from Oct. 29. --The McGraw-Hill Companies Inc rescheduled third-quarter earnings and conference call to Nov. 2 from Oct. 31.
*FDA approves expanded indication for Actemra in rheumatoid arthritis. *Genentech-FDA expanded approved indication for actemra for treatment of. adults with moderately to severely rheumatoid arthritis.
ZURICH, Oct 11- Leading drugmakers will help set up psychological centres for victims of child sex abuse in an effort to counter the long-term health problems suffered by victims.
Oct 11- Roche Holding AG:. *Liberum Capital cuts Roche Holding AG to hold rating. Reuters Station users, click. 1580.
Oct 11- Roche Holding AG:. *Credit Suisse raises Roche price target to Sfr 215 from Sfr 180. Reuters Station users, click. 1580.
NEW YORK, Oct 10- Experimental Alzheimer's drugs from Roche Holding AG and Eli Lilly& Co have been selected for a high-profile clinical trial to test whether it is possible to prevent the brain-wasting disease from developing in at-risk patients.
Oct 10- Experimental drugs from Roche Holding AG. and Eli Lilly& Co have been selected for a global Alzheimer's disease prevention trial, and a second Lilly drug is being considered for inclusion in the study, Washington University said on Wednesday.
Oct 10- Roche Holding AG's experimental drug gantenerumab and Eli Lilly& Co's solanezumab have been chosen to be tested in a high-profile global Alzheimer's disease prevention trial, and a second Lilly medicine is being considered for potential inclusion in the study, Washington University said on Wednesday.
alzheimer's prevention trial-- Washington university. in global trial- Washington university. alzheimer's in different way-- Washington university.
NEW YORK, Oct 10- Experimental Alzheimer's drugs from Roche Holding AG and Eli Lilly& Co have been selected for a high-profile clinical trial to test whether it is possible to prevent the brain-wasting disease from ever developing in at-risk patients.
**ARQULE INC, $2.30, down 53.9 pct The biotechnology company and Japan's Daiichi Sankyo Co Ltd. **GENERAL MOTORS, $23.82, up 3 pct. Hedge fund manager David Einhorn said auto-maker General Motors "is much healthier now," and is getting its product refreshments "right."
The Dow and S&P 500 turned negative while the Nasdaq cut its gains in late morning on Tuesday, with materials and energy shares leading declines on the S&P. **ARQULE INC $2.21 down 55.5 pct The biotechnology company and Japan's Daiichi Sankyo Co Ltd. **FORD MOTOR CO, $9.78, down 1.6 pct.
The Nasdaq Composite Index added 14.98 points, or 0.48 percent, to 3,128.51. **ARQULE INC $2.14, down 57.73 pct The biotechnology company and Japan's Daiichi Sankyo Co Ltd. **SIRIUS XM RADIO INC, $2.62, up 2 pct.
LONDON, Oct 1- The results of two studies into Roche's breast cancer drug Herceptin published on Monday showed that the current standard treatment of taking the drug for a year provides the best outcome for patients.
By Kate Kelland LONDON, Oct 1- Extending treatment with Roche's. Analysts had said the Swiss firm, the world's biggest maker of cancer drugs, could lose up to $1.5 billion in revenue from the blockbuster medicine in the medium term if six months treatment had been shown to be just as effective.
*HERA trial favours status quo, PHARE trial inconclusive* Experts say key message is one year of Herceptin is best* Results limit downside risk for Roche's Herceptin revenues By Kate Kelland LONDON, Oct 1- Extending treatment with Roche'S. Data from both trials were presented at the European Society of Medical Oncology conference in Vienna on Monday.